Orexin/hypocretin in psychiatric disorders: Present state of knowledge and future potential

Neuropsychopharmacology

Volumn 35, Issue 1, 2010, Pages 353-354

  Borgland, Stephanie L ^a   Labouèbe, Gwenaël ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; NEUROLEPTIC AGENT; NEUROPEPTIDE; OREXIN; OREXIN A;

ADDICTION; AROUSAL; CIRCADIAN RHYTHM; DEPRESSION; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DRUG MECHANISM; FEEDING; HUMAN; MENTAL DISEASE; NERVE CELL PLASTICITY; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; SCHIZOPHRENIA; SHORT SURVEY; SLEEP; SYNAPTIC TRANSMISSION; VENTRAL TEGMENTUM;

BRAIN; DEPRESSIVE DISORDER; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MENTAL DISORDERS; NEUROPEPTIDES; SCHIZOPHRENIA; SUBSTANCE-RELATED DISORDERS;

EID: 72049127575     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2009.119     Document Type: Short Survey

References (1)

1. Salomon RM, Ripley B, Kennedy JS, Johnson B, Schmidt D, Zeitzer JM et al (2003). Diurnal variations of cerebrospinal fluid hypocretin-1(orexin-A) levels in control and depressed subjects. Biol Psychiatry 54: 96-104.